Novo Nordisk's (NVO) investors are worried its competition ... Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Novo Nordisk A/S NVO is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar ...